Jonathan Eckard

In a report published Wednesday, Citigroup analyst Jonathan Eckard reiterated a Buy rating on Vical (NASDAQ: VICL), but lowered the price target from $6.00 to $3.00. In the report, Citigroup noted, “We remain long-term buyers of VICL but are lowering our target price to $3 (-$3), representing...

In a report published Monday, Citigroup analyst Jonathan Eckard reiterated a Buy rating on Amarin (NASDAQ: AMRN), and lowered the price target from $13.00 to $11.00. In the report, Citigroup noted, “We are lowering our target price to $11 (-$2) and decreasing Vascepa estimates following lighter...

Leerink Swann analysts Howard Liang and Jonathan Eckard rated shares of Medivation, Inc. (Nasdaq: MDVN) a Market Perform with a valuation of $14. The analysts said that the negative readout for the Phase III CONNECTION trial for Dimebon, without any efficacy signal, leads them to believe that...